KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Buildings (2016 - 2025)

Biogen has reported Buildings over the past 17 years, most recently at $2.1 billion for Q4 2025.

  • For Q4 2025, Buildings rose 8.99% year-over-year to $2.1 billion; the TTM value through Dec 2025 reached $2.1 billion, up 8.99%, while the annual FY2025 figure was $2.1 billion, 8.99% up from the prior year.
  • Buildings for Q4 2025 was $2.1 billion at Biogen, up from $2.0 billion in the prior quarter.
  • Over five years, Buildings peaked at $2.1 billion in Q4 2025 and troughed at $1.6 billion in Q4 2022.
  • A 5-year average of $1.8 billion and a median of $1.7 billion in 2021 define the central range for Buildings.
  • Biggest five-year swings in Buildings: soared 65.78% in 2021 and later fell 6.28% in 2022.
  • Year by year, Buildings stood at $1.7 billion in 2021, then dropped by 6.28% to $1.6 billion in 2022, then grew by 0.53% to $1.6 billion in 2023, then increased by 22.63% to $2.0 billion in 2024, then rose by 8.99% to $2.1 billion in 2025.
  • Business Quant data shows Buildings for BIIB at $2.1 billion in Q4 2025, $2.0 billion in Q4 2024, and $1.6 billion in Q4 2023.